Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: A possible pharmacological target
Basic & Clinical Pharmacology & Toxicology · 2024
DOI: 10.1111/bcpt.14001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Gisele Lopes Cavalcante und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil. Hauptthemen laut MEDLINE: Tissue Inhibitor of Metalloproteinase-1, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
COVID‐19 is a devastating disease and imbalanced matrix metalloproteinase (MMP) activity may contribute to its pathophysiology. This exploratory study examined whether increased circulating concentrations of MMP‐2 and MMP‐9, and their endogenous inhibitors, the tissue inhibitors of MMP (TIMP)‐1, TIMP‐2, TIMP‐3 and TIMP‐4 are persistently found in patients 2 weeks after their recovery from severe or critical COVID‐19 as compared with those in healthy controls. Subjects who had severe ( n = 26) or critical ( n = 25) PCR‐confirmed COVID‐19 and healthy controls ( n = 21) had blood samples drawn 2 weeks after recovery and serum MMP‐2, MMP‐9, TIMP‐1, TIMP‐2, TIMP‐3 and TIMP‐4 were determined using two Human Luminex® Discovery Assays. Circulating MMP activity was also determined by gel zymography. Patients who had severe or critical COVID‐19 had increased circulating MMP‐9 and MMP‐2 concentrations, with increased MMP‐9/TIMP‐1 and MMP‐2/TIMP‐2 ratios indicating increased MMP activity, confirmed by gel zymography (all p < 0.05). Higher circulating MMP‐9 (but not MMP‐2) concentrations were found in critical versus severe COVID‐19 ( p < 0.05). We found increased circulating MMP‐9 and MMP‐2 concentrations and activity many days after recovery from the acute disease, with MMP‐9 levels associated with disease severity. These biochemical alterations suggest that MMP‐2 and MMP‐9 may be important pharmacological targets in COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
- Department of Social Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
- Department of Medicine, Federal University of São Carlos, São Carlos, SP, Brazil.
ORCID-Profile: Jose Eduardo Tanus-Santos
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Cavalcante, G. L., Bonifacio, L. P., Sanches-Lopes, J. M., Puga, F. G., de Carvalho, F. S., Bellissimo-Rodrigues, F., & Tanus-Santos, J. E. (2024). Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: A possible pharmacological target. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14001
Vancouver
Cavalcante GL, Bonifacio LP, Sanches-Lopes JM, Puga FG, de Carvalho FS, Bellissimo-Rodrigues F, et al. Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: A possible pharmacological target. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14001
BibTeX
@article{Cavalcante2024,
author = {Cavalcante, Gisele Lopes and Bonifacio, Lívia Pimenta and Sanches-Lopes, Jéssica Maria and Puga, Fernanda Guioti and de Carvalho, Felipe Santos and Bellissimo-Rodrigues, Fernando and Tanus-Santos, Jose Eduardo},
title = {Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: A possible pharmacological target},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
doi = {10.1111/bcpt.14001}
}
EUVIMED